Schedule and Deadlines:
- The LOI is due by 5 p.m. on February 11, 2020.
- The applicants receive feedback mid-March 2020.
- The full proposal and the final presentation slides are due May 4, 2020.
- The presentation to the advisory board: on May 19, 2020. Please be available from 9am to 2pm.
- The funds will be disbursed on: to be announced.
For additional information, contact Khadija Elabid, Early Stage Business Ventures Manager, at firstname.lastname@example.org, or at x44614 (617-919-4614).
Please read the Guidelines and Policies. A summary is below for your convenience:
These grants provide up to $50,000 to advance early-stage technologies in the validation or proof-of-concept phase. The award is intended to add value to the technology and increase the probability of licensing.
Pilot grants can be used for:
- Prototype development
- Biological target validation and screening
- Animal model development
- Software optimization
- Other advanced pre-commercial research
A minimum of 70 percent of the project will be performed by a contract research organization (CRO). The project must be completed within 12 months from the initial payment.
These grants provide up to $150,000 to advance later-stage technologies whose concept has been proven. Like the pilot grant, this award is intended to add value to the technology and increase the probability of licensing to an established company or startup.
Development grants can be used for:
- Prototype development
- Human clinical studies
- Pre-clinical data packaging
- Drug delivery development
- Large animal studies
- Other advanced pre-commercial research.
A minimum of 70 percent of the project will be performed by a contract research organization (CRO). The project must be completed within 12-18 months from the initial payment.
Applying for grants
- The application must be based on intellectual property (IP) developed at Boston Children’s Hospital with the rights assigned to the hospital. The principal investigator must be a Boston Children’s employee.
- A complete invention disclosure must be on file with the Technology and Innovation Development Office (TIDO).
- For TDGs, at least one patent application for the technology should be filed with the U.S. Patent and Trademark Office prior to submission of the Letter of Intent. The patent strategy and commercialization path for the technology must be well defined.
The TDF’s reviewers, both internal and external, look at the following:
- Medical need or research significance
- Path to market
- Alignment with hospital’s mission
- The potential impact of the grant
- Technical feasibility
- Freedom to operate
- Stage of development
Guidelines for submission of the Letter of Intent
- File an invention disclosure with TIDO.
- Review the evaluation criteria.
- Download the Letter of Intent, complete, and submit by February 8, 2019.
Guidelines for submission of Full Proposal and presentation
- Selected applicants will be invited to submit the full proposal. Download the Full Proposal, and submit as indicated for the Letter of Intent.*
- Prepare a brief 15-minute presentation for the external advisory board. It is recommended that applicants follow the presentation guidelines provided with the full proposal.
- Applicants chosen to receive funding will prepare and submit a project plan.
*Because the evaluation and selection process will place a strong emphasis on the project’s commercial potential, applicants are encouraged to contact the TDF to discuss the full proposal as well as the format and content of the presentation.